73%
jaeinvestorite kontodest jÀÀb selle teenusepakkuja juures hinnavahelepingutega kauplemisel kahjumisse.
Investeerimisega kaasnevad riskid ja need ei ole sobilikud kÔigile investoritele. CFD-d on keerukad instrumendid, millega kaasneb vÔimenduse tÔttu suur risk kaotada raha kiiresti.
73%
jaeinvestorite kontodest jÀÀb selle teenusepakkuja juures CFD-dega kauplemisel kahjumisse.
Palume teil kaaluda, kas CFD-de toimimine on teile arusaadav ja kas te olete valmis vÔtma riski, mis suure tÔenÀosusega on kahjumlik.
73%
jaeinvestorite kontodest jÀÀb selle teenusepakkuja juures hinnavahelepingutega kauplemisel kahjumisse.
Investeerimisega kaasnevad riskid ja need ei ole sobilikud kÔigile investoritele. CFD-d on keerukad instrumendid, millega kaasneb vÔimenduse tÔttu suur risk kaotada raha kiiresti.
73%
jaeinvestorite kontodest jÀÀb selle teenusepakkuja juures CFD-dega kauplemisel kahjumisse.
Palume teil kaaluda, kas CFD-de toimimine on teile arusaadav ja kas te olete valmis vÔtma riski, mis suure tÔenÀosusega on kahjumlik.
Puma Biotechnology Inc
Suletud
SektorTervishoid
6.78 1.95
Ălevaade
Aktsiahinna muutus
24h
Min
6.48
Max
6.83
Sissetulek | 3M 8.8M |
|---|---|
MĂŒĂŒk | 2M 54M |
P/E Sektori keskmine | 9.216 110.024 |
Kasumimarginaal | 16.235 |
Töötajad | 172 |
EBITDA | 2.7M 13M |
JĂ€rgmine tulemuste avaldamine | 26. veebr 2026 |
|---|
Turukapital | 90M 344M |
|---|---|
Eelmine avamishind | 4.83 |
Eelmine sulgemishind | 6.78 |
Uudiste sentiment
By Acuity
34%
66%
96 / 351 Pingereas Healthcare
Tehniline skoor
By Trading Central
Kindlus
Weak Bullish Evidence
Puma Biotechnology Inc Graafik
Mineviku tootlus ei ole usaldusvÀÀrne nÀitaja tulevaste tulemuste kohta.
Seotud uudised
VÔrdlus sarnastega
Hinnamuutus
Puma Biotechnology Inc Prognoos
Sentiment
By Acuity
96 / 351 Pingereas Tervishoid
Uudiste sentiment
Languse mÀrgid
Volatiilsus
Alla keskmise
Uudismaht (RCV)
Alla keskmise
Finantsandmed
MĂŒĂŒgi- ja halduskulud
Tegevuskulud
Maksueelne kasum
MĂŒĂŒk
MĂŒĂŒgikulu
Brutokasum mĂŒĂŒgist
Intressikulud vÔla pealt
EBITDA
Ărikasum
$
EttevÔttest Puma Biotechnology Inc
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
Live chat